You have read all your free articles, to continue reading subscribe to read the rest of this content.
Over 40% of innovative medicines recommended for marketing authorisation in the European Union between 2010 and 2012 originated from small or medium-sized enterprises, says EMA. According to an article published recently in Nature Reviews Drug Discovery, authored by staff members of the European Already a subscriber Login You have read…
Orexo has announced that Boehringer Ingelheim has decided to return the OX-MPI project to Orexo. The project aims to develop products based on specific inhibition of prostaglandin E2 (PGE2) in different disease conditions. Since 2005, Boehringer Ingelheim has been responsible for all research aAlready a subscriber Login You have read all your…
RhoVac has announced that Mount Sinai hospital in New York is being initiated as the latest addition to US trial centres in the company's clinical phase IIb study, “BRaVac”, in prostate cancer. The participation of Mount Sinai was directly caused by the FDA approval of RhoVac’s Fast Track DAlready a…
AlzeCure announced that data from its TrkA and TrkB positive allosteric modulator program for Alzheimer’s disease will be presented at the 17th International Conference on Alzheimer’s Drug Discovery in Jersey City, NJ, USA. The oral presentation will include preclinical in vivo Proof-of-PrinciplAlready a subscriber Login You have read all your…
